Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer

Prostate cancer is the most common malignancy in men in the United States. While androgen deprivation therapy results in tumor responses initially, there is relapse and progression to metastatic castration resistant prostate cancer. Currently, all prostate cancer patients receive essentially the same treatment and there is a need for clinically applicable technologies to provide predictive biomarkers towards personalized therapies. Genomic analyses of tumors are used for clinical applications but with a paucity of obvious driver mutations in metastatic castration resistant prostate cancer, other applications, such as phosphoproteomics, may complement this approach. Immunohistochemistry and reverse phase protein arrays are limited by the availability of reliable antibodies and evaluates a pre-selected number of targets. Mass spectrometry-based phosphoproteomics has been used to profile tumors consisting of thousands of phosphopeptides from individual patients after surgical resection or at autopsy. However, this approach is time consuming and while a large number of candidate phosphopeptides are obtained for evaluation, limitations are reduced reproducibility, sensitivity, and precision. Targeted mass spectrometry can help eliminate these limitations and is more cost effective and less time consuming making it a practical platform for future clinical testing. In this review, we discuss the use of phosphoproteomics in prostate cancer and other clinical cancer tissues for target identification, hypothesis testing, and possible patient stratification. We highlight the majority of studies that have used phosphoproteomics in prostate cancer tissues and cell lines and propose ways forward to apply this approach in basic and clinical research. Overall, the implementation of phosphoproteomics via targeted mass spectrometry has tremendous potential to aid in the development of more rational, personalized therapies that will result in increased survival and quality of life enhancement in patients suffering from metastatic castration resistant prostate cancer.

Abstract licence: CC BY

1. 6.

   Identification of prostate cancer biomarkers in urinary exosomes · 2015

2. 37.

   The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients · 2013

3. 40.

   Proteomic Profiling of Exosomes Leads to the Identification of Novel Biomarkers for Prostate Cancer · 2013

4. 96.

   Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer · 2004

5. 119.

   Exosomes in Cancer Diagnostics · 2017

127 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.